Effectiveness of intensive insulin therapy by multiple daily injections and continuous subcutaneous infusion: A comparison study in type 2 diabetes with conventional insulin regimen failure

Hormone and Metabolic Research

Volumn 39, Issue 3, 2007, Pages 224-229

  Berthe, E ^a   Lireux, B ^a   Coffin, C ^a   Goulet Salmon, B ^b   Houlbert, D ^b   Boutreux, S ^a   Fradin, S ^a   Reznik, Y ^a,c  

^a CAEN UNIVERSITY HOSPITAL   (France)

^b Alencon Hospital   (France)

^c CHU CÔTE DE NACRE   (France)

Author keywords

Continuous glucose monitoring system; Continuous subcutaneous insulin infusion; Humalog Mix50; Type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C; HUMALOG MIX50; INSULIN LISPRO; INSULIN LISPRO PLUS ISOPHANE INSULIN; ISOPHANE INSULIN; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN PUMP; INSULIN TREATMENT; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SATISFACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT FAILURE; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; AREA UNDER CURVE; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMOGLOBINS; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; INSULIN INFUSION SYSTEMS; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; PATIENT SATISFACTION; QUESTIONNAIRES; TREATMENT FAILURE;

EID: 34147219083     PISSN: 00185043     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-970423     Document Type: Article

References (23)

1. Janka HU, Plewe G, Kliebe-Frisch C, Schweitzer MA: Starting insulin for type 2 diabetes with insulin glargine added to oral agents versus twice-daily premixed insulin alone [Abstract]. Diabetologia 2003; 46 (Suppl 2): A268
2. Riddle MC, Rosenstock J, Gerich J: Insulin Glargine 4002 Study Investigators: the treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-3086
3. Fritsche A, Schweitzer MA, Hating HU, 4001 Study Group: Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 2003; 138: 952-959
4. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853
5. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O: Multi-factorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393
6. Abraira C, Colwell JA, Nuttall FQ, Sawin CT, Nagel NJ, Comstock JP, Emanuele NV, Levin SR, Henderson W, Lee HS: Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes. Diabetes Care 1995; 18: 1113-1123
7. Charbonnel B, Balarac N, Cazeneuve B, Augendre-Ferrante B, Le Thai F, Drouin P: Schema survey. Which are the insulin treatment regimens used in France? The "Schema survey". Diabetes Metab 2001; 27: 591-597
8. Implementation of treatment protocols in the Diabetes Control and Complications Trial. Diabetes Care 1995; 18: 361-376
9. Hanaire-Broutin H, Melki V, Bessieres-Lacombe S, Tauber JP, The Study Group for the Development of Pump Therapy in Diabetes: Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment: a randomized study. Diabetes Care 2000; 23: 1232-1235
10. Doyle FA, Weinzimer SA, Steffen AT, Ahem JA, Vincent M, Tamborlane WV: A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care 2004; 27: 1554-1558
11. Pouwels MJ, Tack CJ, Hermus AR, Lutterman JA: Treatment with intravenous insulin followed by continuous subcutaneous insulin infusion improves glycaemic control in severely resistant Type 2 diabetic patients. Diabet Med 2003; 20: 76-79
12. Jennings AM, Lewis KS, Murdoch S, Talbot JF, Bradley C, Ward JD: Randomized trial comparing continuous subcutaneous insulin infusion and conventional insulin therapy in type II diabetic patients poorly controlled with sulfonylureas. Diabetes Care 1991; 14: 738-744
13. Raskin P, Bode BW, Marks JB, Hirsch IB, Weinstein RL, McGill JB, Peterson GE, Mudaliar SR, Reinhardt RR: Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study. Diabetes Care 2003; 26: 2598-2603
14. American Diabetes Association Nutrition Principles and Recommendations in Diabetes (Position Statement). Diabetes Care 2004; 26 (Suppl 1): S36-S46
15. Schernthaner G, Kopp HP, Ristic S, Muzyka B, Peter L, Mitteregger G: Metabolic control in patients with type 2 diabetes using Humalog Mix50 injected three times daily: crossover comparison with human insulin 30/70. Horm Metab Res 2004; 36: 188-193
16. Weinrrob N, Schechter A, Benzaquen H, Shalitin S, Lilos P, Galatzer A, Phillip M: Glycemic patterns detected by continuous subcutaneous glucose sensing in children and adolescents with type 1 diabetes mellitus treated by multiple daily injections vs continuous subcutaneous insulin infusion. Arch Pediatr Adolesc Med 2004; 158: 677-684
17. Abraira C, Henderson WG, Colwell JA, Nuttall FQ, Comstock JP, Emanuele NV, Levin SR, Sawin CT, Silbert CK: Response to intensive therapy steps and to glipizide dose in combination with insulin in type 2 diabetes. VA feasibility study on glycemic control and complications (VA CSDM). Diabetes Care 1998; 21: 574-579
18. Feinglos MN, Thacker CH, English J, Bethel MA, Lane JD: Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes. Diabetes Care 1997; 20: 1539-1542
19. Bastyr EJ, 3rd, Stuart CA, Brodows RG, Schwartz S, Graf CJ, Zagar A, Robertson KE: Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group. Diabetes Care 2000; 23: 1236-1241
20. Bastyr EJ, 3rd, Huang Y, Brunelle RL, Vignati L, Cox DJ, Kotsanos JG: Factors associated with nocturnal hypoglycaemia among patients with type 2 diabetes new to insulin therapy: experience with insulin lispro. Diabetes Obes Metab 2000; 2: 39-46
21. Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, Hu P, Bode B, Garber A: Initiating insulin therapy in type 2 diabetes: a comparison between biphasic and basal insulin analogs. Diabetes Care 2005; 28: 260-265
22. Ilkova H, Glaser B, Tunckale A, Bagriacik N, Cerasi E: Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care 1997; 20: 1353-1356
23. Wainstein J, Metzger M, Boaz M, Minuchin O, Cohen Y, Yaffe A, Yerushalmy Y, Raz I, Harman-Boehm I: Insulin pump therapy vs. multiple daily injections in obese Type 2 diabetic patients. Diabet Med 2005; 22: 1037-1046